Outcome of the meeting of the Board of Directors held on Thursday May 29, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Shukra Pharmaceuticals approved audited standalone financial results for Q4 and FY25 on May 29, 2025, with an unmodified (clean) opinion from statutory auditor M/s MAAK and Associates. Full-year FY25 revenue from operations fell sharply to ₹3,258.73 lakhs from ₹7,457.29 lakhs in FY24, a drop of roughly 56%. Full-year net profit declined to ₹957.51 lakhs (from ₹1,853.72 lakhs), with EPS at ₹0.22 vs ₹4.23 previously. The revenue drop appears linked to a business model shift — purchases of stock-in-trade fell from ₹3,040.52 lakhs to zero. On a positive note, Q4 FY25 showed a recovery, with revenue rising to ₹1,326.98 lakhs (vs ₹1,088.39 lakhs in Q4 FY24) and Q4 net profit at ₹538.64 lakhs (vs ₹398.59 lakhs). Operating cash flow turned strongly positive at ₹791.84 lakhs (from negative ₹519.68 lakhs), and the company paid dividends of ₹437.88 lakhs during the year.
The sharp full-year revenue and profit decline reflects a strategic exit from stock-in-trade business, not a loss of operational health — Q4 rebound and positive operating cash flow suggest stabilization. Shareholders can take comfort from the clean audit opinion and dividend payout, but should monitor whether the new operating model delivers sustained growth.